Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667829 | 0.86 | MAPK1 (0.44) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL23112391 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL23112345 | 0.80 | CTNNB1 (0.42) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL21262192 | 0.80 | KDM4E (0.45) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL2427488 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL29091652 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL30615205 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL10792029 | 0.76 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL17996673 | 0.76 | HSD17B10 (0.38) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL29054677 | 0.75 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| CN-115215808-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2022-10-21 | — | — | CN | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | KDM4E 3091/4885ALDH1A1 2649/4885HSD17B10 3486/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | KDM4E 3422/4885ALDH1A1 2584/4885HSD17B10 3362/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | KDM4E 3386/4885ALDH1A1 2784/4885HSD17B10 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.